Bionano Genomics Symposium Showcases 70% SV Detection and FDA Backing of OGM
Bionano Genomics showcased 11 OGM studies at Symposium 2026, with 1,150 participants from 73 countries revealing detection of structural variants in 70% of 201 sarcoma samples and full concordance with FISH in 214 myeloma cases. Presenters noted FDA backing of OGM’s high-sensitivity genome integrity analysis for cell and gene therapy.
1. Symposium Overview
Bionano Genomics hosted its Symposium 2026 Day 2 session on optical genome mapping (OGM) with 11 presentations focusing on oncology and bioprocessing. Attendance grew to 1,150 registered participants representing 73 countries, marking the largest global event dedicated to OGM and Bionano’s solutions this year.
2. Oncology Study Highlights
Presenters reported new OGM data, including a prospective study in 214 multiple myeloma samples demonstrating full concordance with FISH and detection of additional structural complexities. In rare sarcoma research, OGM uncovered structural variants in over 70% of 201 soft tissue samples, revealing cryptic rearrangements missed by conventional karyotyping.
3. FDA Recognition and Cell/Gene Therapy Applications
The session highlighted FDA recognition of OGM’s high-sensitivity genome integrity analysis for cell and gene therapy development. Researchers showcased OGM’s capacity to detect off-target modifications and subtle genomic changes in engineered iPSC lines, supporting its use in bioprocessing and quality control of gene-editing applications.